CM Subtypes | HCM | DCM | ARVC/D | NCM | RCM & Iron mediated CM | ToF16 |
---|---|---|---|---|---|---|
Incidence (I) OR Prevalence (P) | P = 1:500 in absence of aortic valve disease or systemic hypertension | I = 5-8 cases /100,000 P = 36 cases /100,000 | I = 1/ 10,000 | I = 0.05% to 0.24% | I = 11.4% to 15.1% in Thalassemia major patients Transfusion Dependent | I = 9/1000 live births |
#Patients evaluated for CM | 46 | 129 | 44 | 31 | 35 | 684 |
Total number of positive diagnosis w/ CMRI CM | 11 | 18 | 4 | 15 | 12 | 119 |
cMRI-based QUANTITATIVE markers | ||||||
LV myocardial wall thickness | ABNL | ABNL | NL | ABNL | ABNL | NL |
LV mass index | ABNL | ABNL | NL | ABNL | ABNL | NL |
LV Volume index | ABNL | ABNL | NL | ABNL | ABNL | ABNL |
RV Volume index | NL | ABNL | ABNL | NL | ABNL | ABNL |
cMRI-based QUALITATIVE markers | ||||||
Myocardial Delayed Enhancement | +/- | +/- | +/- | +/- | +/- | + |
Wall motion abnormalities | +/- | +/- | +/- | +/- | +/- | +/- |